{ 216件 }
Takahashi Y, Nomoto H*, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H*.
Improvement of glycemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicenter, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1
study)
Diabetes Obes Metab, in press
IF = 6.408
Miyoshi H, Matsuhisa M, Yabe D, Takahashi Y, Morimoto Y, Terauchi Y.
Use of iGlarLixi for the management of type 2 diabetes in Japanese clinical practice: prior treatment subgroup analysis of the SPARTA Japan study.
Diabetes Ther. 2023 in press
IF = 3.605
Karino K, Kono M, Kanda M, Atsumi T.
Reply.
Arthritis Rheumatol. in press.
IF=15.483
Kato M, Ninagawa K, Atsumi T.
Comment on: Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study: Reply.
Rheumatology (Oxford). in press
IF=7.046
Aso K, Fujieda Y, Atsumi T.
Homonymous hemianopsia and headache with mass-like lesion Annals of the Rheumatic Diseases.
IF 19.103
Scherlinger M, Pan W, Hisada R, Boulougoura A, Yoshida N, Vukelic M, Umeda M, Krishfield S, Tsokos MG, Tsokos GC.
Phosphofructokinase P fine-tunes T regulatory cell metabolism, function, and stability in systemic autoimmunity.
Sci Adv. 2022;8(48):eadc9657.
IF = 14.980
Oe Y, Nomoto H, Nakamura A, Kuwabara S, Takahashi Y, Yasui A, Izumihara R, Miya A, Kameda H, Cho KY, Atsumi T, Miyoshi H.
Effect of beta-cell function on glucose variability when switching from insulin degludec plus a dipeptidyl peptidase-4 inhibitor to insulin degludec/liraglutide: preliminary results from a pilot study Int J Endocrinol, in press.
IF：2.803
Nagasaka K, Amano K, Dobashi H, Nagafuchi H, Sada K, Komagata Y, Yamamura M, Kato M, Endo T, Nakaya I, Takeuchi T, Murakawa Y, Sugihara T, Saito M, Hayashi T, Furuta S, Tamura N, Karasawa K, Banno S, Endo S, Majima M, Kaname S, Arimura Y, Harigai M.
Nation-wide Cohort Study of Remission Induction Therapy using Rituximab in Japanese patients with ANCA-Associated Vasculitis:
effectiveness and safety in the first six months.
Modern Rheumatology. in press.
IF: 2.862
Abe N, Kono Michihiro, Kono Michihito*, Katsuyama T, Ohmura K, Sato T, Karino K, Fujieda Y, Kato M, Hasebe R, Murakami M, and Atsumi T.
Cytokine and chemokine multiplex analysis-based exploration for potential treatment and prognostic prediction in large-vessel
vasculitis: a preliminary observational study. Frontiers in Immunology in press
IF=8.786
第32回日本リウマチ学会北海道・東北支部学術集会 若手リウマチ医奨励賞受賞者セッション 優秀賞 鎌田 和郎先生